Evidence map›Paper›PMID 41981590›Full record

ArticleJournal of nanobiotechnology2026

Programmable DNAzyme nanocatalysts orchestrate redox-immune coupling for time-gated cancer immunomodulation.

Lu Wang, Rongping Luo, Lingxiu Zou, Xiaojing Liu, Zhuojia Tang, Fengqi Dong, Zhen Wang, Jianxin Lyu, Yi Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lu WangLaboratory Medicine Center, Department of Clinical Laboratory, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Rongping LuoSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Lingxiu ZouSchool of Public Health, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Xiaojing LiuSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Zhuojia TangSchool of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Fengqi DongCixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, 315302, Zhejiang, China.
Zhen WangLaboratory Medicine Center, Department of Transfusion Medicine, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Jianxin LyuLaboratory Medicine Center, Department of Clinical Laboratory, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. jxlu313@163.com.
Yi ZhangLaboratory Medicine Center, Department of Transfusion Medicine, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. zhangyi8310@sina.com.

Funding

Department of Education of Zhejiang Province Y202559865Hangzhou Medical College, China 00004E1RCYJ2408National Natural Science Foundation of China U22A20342 to J.L.
6 · The paper itself

Abstract

Immune activation within tumors is governed by highly dynamic redox and mitochondrial signaling events, yet the temporal organization of these processes remains poorly defined. Here, we report a programmable DNAzyme nanocatalyst (APTZ) that enables time-dependent redox-immune coupling by translating intracellular catalytic activity into a transient biochemical signal window. The APTZ platform integrates ZnO nanoparticles, a catalase-targeting DNAzyme, and a tumor-homing aptamer, allowing acid-triggered Zn

Indexed as

DNA, CatalyticImmunomodulationNanoparticlesNeoplasmsAnimalsCatalaseCatalysisCell Line, TumorcGAS-STING Signaling PathwayDNA, MitochondrialHumansImmunotherapyOxidation-ReductionReactive Oxygen SpeciesCatalaseDNA, CatalyticDNA, MitochondrialReactive Oxygen SpeciesCancer immunotherapycGAS-STING signalingDNAzyme nanocatalystMitochondrial dysfunctionRedox regulation

Identifiers

PMID41981590
PMCPMC13251222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.